IRIDEX Cash Flow from Financial Activities 2010-2025 | IRIX
IRIDEX cash flow from financial activities from 2010 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
IRIDEX Annual Cash Flow Financial
(Millions of US $) |
| 2024 |
$3 |
| 2023 |
$0 |
| 2022 |
$0 |
| 2021 |
$9 |
| 2020 |
$2 |
| 2019 |
$0 |
| 2018 |
$10 |
| 2017 |
$2 |
| 2016 |
$15 |
| 2015 |
$-1 |
| 2014 |
$-3 |
| 2013 |
$1 |
| 2012 |
$-2 |
| 2011 |
$0 |
| 2010 |
$-2 |
| 2009 |
$-2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Computer and Technology |
Laser Systems and Components |
$0.017B |
$0.049B |
|
IRIDEX Corporation is the leading worldwide provider of semiconductor-based laser systems used to treat eye diseases in ophthalmology and skin lesions in dermatology. The products are sold in the United States predominantly through a direct sales force and internationally through independent distributors. The company markets the products using three brand names: IRIS Medical to the ophthalmology market, IRIDERM to the dermatology market, and Light Solutions to the research market.
|
